| Document |
Document Title |
|
WO/2023/229859A1 |
During the production of Hexahydro-1, 3, 5-trinitro-l, 3, 5-triazine and Octahydro-1,3, 5, 7-tetranitro-l, 3,5, 7-tetrazocine via the Bachmann nitrolysis process, it is necessary to recover the entire mass of acetic acid and restore it t...
|
|
WO/2023/225327A1 |
Compounds, compositions, and methods for making and using the compounds for treatment of cancer are provided herein. Mechanistically, these compounds were found to bind to RPS23 and were effective in activating the inducible stress respo...
|
|
WO/2023/224981A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2023/225300A2 |
This disclosure relates to compounds, pharmaceutical compositions, and methods of treating or preventing sickle cell disease or conditions associated thereto. In certain embodiments, the compounds are 1-(thiazol-2-yl)urea derivatives. In...
|
|
WO/2023/219106A1 |
The present invention addresses the problem of providing a solid derivative of 2-methyl-2-thiazoline that is easy to handle during formulation and is useful as an active pharmaceutical ingredient. The present invention provides: a 1,5-na...
|
|
WO/2023/216992A1 |
Provided are a cyanine-trehalose compound, a method for preparing same, and use thereof. Specifically, the compound is represented by formula I. The cyanine-trehalose compound can be used for detecting Mycobacterium tuberculosis, and fea...
|
|
WO/2023/210772A1 |
A first problem to be addressed by the present invention is to provide a photoelectric conversion element that has excellent quantum efficiency when receiving blue light. A second problem to be addressed by the present invention is to pr...
|
|
WO/2023/210599A1 |
The present invention provides a compound represented by general formula[1] and having a DDR1 kinase inhibitory activity, a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable...
|
|
WO/2023/211945A1 |
This application is directed to inhibitors of represented by the following structural formula, and methods for their use in modulating MCT in a disease or disorder, such as cancer or neurodegenerative diseases.
|
|
WO/2023/211938A1 |
This application is directed to modulators of MCT represented by the following structural formula (I) and methods for their use, such as to treat cancer or neurodegenerative diseases.
|
|
WO/2023/211942A1 |
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable prodrugs, solvates, or salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed he...
|
|
WO/2023/198095A1 |
The present invention relates to the field of pharmaceuticals, and particularly provides use of a nitrothiazole derivative in preparing a bacteriostat for inhibiting Helicobacter pylori. The amino nitrothiazole derivative has a structure...
|
|
WO/2023/200315A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2023/194496A1 |
A process for the preparation of compound of formula (I) is provided: where R, R1, R2, R3 and R4 are as defined in the description.
|
|
WO/2023/186126A1 |
The present invention relates to an aromatic ring compound and use thereof. Specifically provided is a compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable sal...
|
|
WO/2023/185831A1 |
The present application relates to a compound containing a thiazole ring, and specifically to a compound of formula I, a preparation method therefor, a pharmaceutical composition comprising same, and use thereof in treating diseases such...
|
|
WO/2023/192388A1 |
The disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (...
|
|
WO/2023/192595A1 |
Disclosed herein are thiazolylphenol compounds 1 and methods of using the same for the treatment of subjects in need of a treatment for an infection by a microbe.
|
|
WO/2023/182775A1 |
The present invention pertains to: a novel aromatic heterocyclic compound that can be used in an organic light-emitting diode; and an organic light-emitting diode including same.
|
|
WO/2023/176487A1 |
The production method according to the present invention is characterized in that a D-amino acid oxidase used in step 2 in the scheme shown below is a polypeptide selected from the below-mentioned polypeptides (a) to (c). According to th...
|
|
WO/2023/177217A1 |
The present invention relates to: a novel aromatic heterocyclic compound to be used in an organic light-emitting diode; and the organic light-emitting diode comprising same.
|
|
WO/2023/176458A1 |
Provided is a disinfecting composition having an excellent controlling effect against plant disease.　This disinfecting composition contains a thiazole carboxylic acid hydrazide compound represented by formula (I) (where each symbol is ...
|
|
WO/2023/168484A1 |
Compounds of Formula (A) and methods for use as agricultural chemicals, including herbicides: Formula (A)
|
|
WO/2023/170024A1 |
The present disclosure relates to compounds which bind Ca2+/calmodulin dependent protein kinase II. It also relates to such compounds for use in the treatment of CNS disorders with sleep disturbances and acute brain injury.
|
|
WO/2023/166303A1 |
The invention relates to compounds of formula (I): (I) and related aspects.
|
|
WO/2023/165334A1 |
The present invention provides keto amide derivatives and the pharmaceutical use thereof, belonging to the technical field of organic synthesis drugs. Specifically provided are a compound represented by formula I, or a pharmaceutically a...
|
|
WO/2023/163945A1 |
The instant disclosure provides methods and pharmaceutical compositions for the treatment of congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS), as well as a method of reducing androgen levels in a human in need th...
|
|
WO/2023/160582A1 |
Provided in the present invention are a thiazolamine MBL inhibitor, and a preparation method therefor and the use thereof, which belong to the field of medical chemistry. The thiazolamine MBL inhibitor is a compound represented by formul...
|
|
WO/2023/160634A1 |
Disclosed in the present invention are benzothiazole compounds as well as a preparation method therefor and the use thereof. The compounds have a great inhibition effect on SARS-CoV-2 and can be used for resisting the novel coronavirus. (I)
|
|
WO/2023/158602A1 |
Disclosed are compounds of Formula I including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein G, Z, L, J, A and T are as defined in the disclosure. Also disclosed are compositions containing the compound...
|
|
WO/2023/158679A2 |
Disclosed herein are structures, compositions and syntheses of pharmaceutically relevant compounds inspired by thiostrepton, as well as methods of treating cancer with such compounds.
|
|
WO/2023/158866A2 |
The disclosure includes a method of inhibiting a eukaryotic translation initiation factor 3e (eIF3e) comprising contacting the eIF3e with a compound or salt of the Formula I, where the variables, e.g., Y, Z, R, and R1R11 are defined here...
|
|
WO/2023/158795A1 |
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
|
|
WO/2023/152691A1 |
The present invention relates to a process for the preparation of Ponesimod of formula I and its intermediates thereof.
|
|
WO/2022/178428A9 |
The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of an extracellular or cell surface protein. In certain embodiments, the extracellular protein mediates a disease a...
|
|
WO/2023/152182A1 |
Present invention relates to a compound according to formula (II): and all stereoisomers, racemic mixtures, tautomers, pharmaceutically acceptable salts, prodrugs, hydrates, solvates and polymorphs thereof, as well as pharmaceutical comp...
|
|
WO/2023/152415A1 |
The present invention relates to a compound of formula I, wherein the groups R1 to R5 and Cy have the meaning described in the description, for use thereof in the treatment and/or prevention of an infection or disease caused by the infec...
|
|
WO/2023/151897A1 |
The invention relates to compounds of general formula (I).
|
|
WO/2023/147344A1 |
The present disclosure provides compounds of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of inhibiting isocitrate dehydrogenase 1 (ID...
|
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
|
WO/2023/146897A1 |
Described herein are selective HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular dis...
|
|
WO/2023/143603A1 |
Use of a compound of Formula I for treating atherosclerosis and related diseases, disorders and conditions in a subject in need of such treatment, wherein the subject in need of such treatment is a subject carrying one or more genetic mu...
|
|
WO/2023/141262A1 |
Disclosed herein are small molecule activators of the B-cell lymphoma-2-associated X protein (BAX). Also disclosed are compositions containing one or more BAX activators and uses thereof in the treatment of cancer, including leukemia and...
|
|
WO/2023/136457A1 |
The present invention relates to a novel compound and an organic light-emitting device comprising same.
|
|
WO/2023/135303A1 |
The present invention provides solid crystalline forms of compounds useful as helicase-primase inhibitors, compositions thereof, methods of producing the same, and methods of using the same in the treatment of herpes simplex infection an...
|
|
WO/2023/133875A1 |
Provided is a multifunctional group metal corrosion inhibitor, as shown in one or more of formula (I-a) to formula (I-c). The metal corrosion inhibitor is a multifunctional group metal corrosion inhibitor comprising Schiff base or a deri...
|
|
WO/2023/018472A9 |
N,N-disubstituted arylamine compounds and to their use as integrin agonists for enhancing binding of integrin-expressing cells to integrin-binding ligands or receptors.
|
|
WO/2023/131690A1 |
The invention relates to substituted heterocycles of the general formula (I), wherein W is thiazole, thiophene, pyrazole, imidazole or isoxazole, and the use of the compounds of the present invention for the treatment and/or prevention o...
|
|
WO/2023/131677A1 |
The inventors have succeeded in developing urea, oxalamide, amide, thiourea, carbamate or ester compounds, in particular urea compounds, bearing two side groups, one of which carries a hydroxyphenyl or phenyl moiety, in particular a hydr...
|
|
WO/2023/131951A1 |
Novel non-coded amino acids derivatives having herbicidal activity, agricultural compositions, process for their manufacture and their use in crop protection are provided.
|
